Nanovibronix Inc
NASDAQ:NAOV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Nanovibronix Inc
EPS (Diluted)
Nanovibronix Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Nanovibronix Inc
NASDAQ:NAOV
|
EPS (Diluted)
-$6
|
CAGR 3-Years
76%
|
CAGR 5-Years
64%
|
CAGR 10-Years
45%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
EPS (Diluted)
$1
|
CAGR 3-Years
63%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
EPS (Diluted)
$1
|
CAGR 3-Years
-9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
9%
|
|
|
Stryker Corp
NYSE:SYK
|
EPS (Diluted)
$8
|
CAGR 3-Years
11%
|
CAGR 5-Years
15%
|
CAGR 10-Years
8%
|
|
|
Abbott Laboratories
NYSE:ABT
|
EPS (Diluted)
$3
|
CAGR 3-Years
3%
|
CAGR 5-Years
2%
|
CAGR 10-Years
8%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
EPS (Diluted)
$7
|
CAGR 3-Years
29%
|
CAGR 5-Years
22%
|
CAGR 10-Years
16%
|
|
Nanovibronix Inc
Glance View
NanoVibronix, Inc. engages in the development of noninvasive biological response-activating devices. The company is headquartered in Elmsford, New York and currently employs 12 full-time employees. The company went IPO on 2015-04-24. The firm is focused on developing noninvasive biological response-activating devices utilizing its low intensity surface acoustic wave (SAW) technology, which targets biofilm prevention, pain therapy, and wound healing and can be administered at home, without the assistance of medical professionals. Its primary products, which are in various stages of clinical and market development consist of UroShield, PainShield and WoundShield. Its PainShield family of products include PainShield MD, PainShield Plus and PainShield Relief. Each of its UroShield, PainShield, and WoundShield products employs a small, disposable transducer that transmits low frequency, low intensity ultrasound acoustic waves that seek to repair and regenerate tissue, musculoskeletal and vascular structures, and decrease biofilm formation on urinary catheters and associated urinary tract infections. Its wholly owned subsidiary is NanoVibronix Ltd.
See Also
What is Nanovibronix Inc's EPS (Diluted)?
EPS (Diluted)
-6.1
USD
Based on the financial report for Sep 30, 2025, Nanovibronix Inc's EPS (Diluted) amounts to -6.1 USD.
What is Nanovibronix Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
45%
Over the last year, the EPS (Diluted) growth was 95%. The average annual EPS (Diluted) growth rates for Nanovibronix Inc have been 76% over the past three years , 64% over the past five years , and 45% over the past ten years .
